Winning approval to target the 15,000 U.S. patients with locally advanced pancreatic cancer is the first step in a broader expansion in the tumor type.

The company struck three deals in New York last year as part of its push to acquire hospital and regional testing labs.

New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

Torres joins the medtech lobby from the FDA’s Center for Devices and Radiological Health, where she was associate director ...

Johnson & Johnson, Boston Scientific and Abbott were among the companies showcasing new data on atrial fibrillation ...

Neurent Medical has raised 62.5 million euros ($74 million) to commercialize a device that treats a common nasal condition, ...

An expanded collaboration between the two organizations will focus on prostate cancer and metastatic liver tumors, in addition to neurodegenerative disease.

Surgeons interested in robotic technology but wanting a simpler system than existing platforms are the target market for the ...

Zimmer Biomet expects the shift of its U.S. salesforce to a more specialized, direct approach will help it better compete in ...

Orthopedics was the most active area over the second half of 2025, with the FDA issuing 13 breakthrough designations to ...

Abbott on Friday presented one-year clinical trial results for the Volt pulsed field ablation system alongside six-month CE ...

Hospital demand for IV solutions in the U.S. is lower than before Hurricane Helene, the company said.